Cellular and tissue distribution of intravenously administered agalsidase alfa. 2007

Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.

alpha-Galactosidase A is the lysosomal hydrolase that is deficient in patients with Fabry disease. Intravenous infusion of agalsidase alfa, a preparation of alpha-Galactosidase A, is used for enzyme replacement therapy (ERT) in patients with Fabry disease. Although ERT appears to show some beneficial effects, most patients show only a modest response. We investigated using immunohistochemistry the relative tissue and cellular distribution of agalsidase alfa after a single intravenous injection in a mouse knockout model of Fabry disease. Specific immunostaining for agalsidase alfa was found only in liver, kidney, heart, testes, adrenal gland, spleen and bone marrow. There was no difference in distribution of the infused enzyme distribution among tissues sampled 4, 24, and 48h post-injection. The intracellular localization of immunopositivity varied considerably between organs with vascular endothelium being the most commonly positive site. alpha-Galactosidase A specific activity in tissue homogenates matched the relative extent of agalsidase alfa immunostaining distribution in the same organs. We conclude that intravenously injected agalsidase alfa has a very heterogeneous systemic distribution using an immunostaining technique.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000519 alpha-Galactosidase An enzyme that catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-galactosides including galactose oligosaccharides, galactomannans, and galactolipids. Beano,Melibiase,alpha-D-Galactopyranosidase,alpha-D-Galactosidase,alpha-Galactisidase,alpha-Galactosidase A,alpha-Galactosidases,alpha D Galactopyranosidase,alpha D Galactosidase,alpha Galactisidase,alpha Galactosidase,alpha Galactosidase A,alpha Galactosidases
D000795 Fabry Disease An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders. Anderson-Fabry Disease,Angiokeratoma Corporis Diffusum,Angiokeratoma Diffuse,Angiokeratoma, Diffuse,Ceramide Trihexosidase Deficiency,Fabry's Disease,GLA Deficiency,Hereditary Dystopic Lipidosis,alpha-Galactosidase A Deficiency,alpha-Galactosidase A Deficiency Disease,Anderson Fabry Disease,Deficiency, Ceramide Trihexosidase,Deficiency, GLA,Deficiency, alpha-Galactosidase A,Diffuse Angiokeratoma,Lipidosis, Hereditary Dystopic,alpha Galactosidase A Deficiency,alpha Galactosidase A Deficiency Disease
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
August 2011, Toxicology letters,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
March 2014, Nanotoxicology,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
January 1993, ASAIO journal (American Society for Artificial Internal Organs : 1992),
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
March 2008, Archives of toxicology,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
January 1989, Drug metabolism and disposition: the biological fate of chemicals,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
July 2015, Chemical science,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
February 1950, Archives of industrial hygiene and occupational medicine,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
January 2015, JIMD reports,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
January 2008, Molecular genetics and metabolism,
Gary J Murray, and Miriam R Anver, and Maureen A Kennedy, and Jane M Quirk, and Raphael Schiffmann
March 2007, Expert review of endocrinology & metabolism,
Copied contents to your clipboard!